Company ProfilePremium

AstraZeneca Pharma India Limited

Company Profile Analysis

Tickers: ASTRAZEN.NS, 506820.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
AstraZeneca Pharma India Limited - Company showcase

Year Founded & Workforce

1979

760 Employees

AstraZeneca Pharma India Limited logo

AstraZeneca Pharma India Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

AstraZeneca Pharma India Limited Overview

AstraZeneca Pharma India Limited is the publicly listed Indian commercial arm of AstraZeneca PLC, operating as a specialty, innovation-only pharmaceutical marketer focused on Oncology, Biopharmaceuticals (Cardiovascular, Renal & Metabolism; Respiratory & Immunology; Vaccines & Immune Therapies) and, since FY2025, Rare Disease (Alexion portfolio). Unlike India's generic-led majors, AZPIL sells patented and branded medicines sourced predominantly from its parent's global supply network, and it has now completed its exit from in-country manufacturing (Bengaluru site). Revenue has compounded at roughly 30% a year since FY2022, reaching INR 22,756 M in FY2026, driven overwhelmingly by oncology brands, which grew 44% to INR 16,101 M. The company secured 11 regulatory approvals for new medicines and indications in FY2026. The investment case combines best-in-class top-line growth and a debt-free balance sheet against thin, compressing margins, heavy related-party sourcing, price-control exposure, recent senior-management turnover, and a valuation near 100x trailing earnings.


Company's own description

Exchange-filed descriptions characterise the company as engaged in the manufacture, distribution and marketing of pharmaceutical products, and also as a provider of clinical-trial services to an overseas group company (FY2025 Annual Report, as quoted by aggregators). The company's October 2026 press release describes the AstraZeneca organisation in India as science-led, focused on discovery, development and commercialisation of prescription medicines across Oncology, Biopharmaceuticals and Rare Disease, with operations in India spanning commercial operations, site management and clinical monitoring, technology, R&D and global business services.

Independent characterisation

AZPIL is best understood as a "pipeline-import, commercialise-locally" model:

  1. Product sourcing. Finished medicines are imported from AstraZeneca group entities (principally AstraZeneca AB, Sweden and AstraZeneca UK). Related-party transactions with these entities were reported by one analysis at about 72.9% of FY2025 revenue (CompoundingAI, Q1 FY2027 results note) — this is the scale of related-party flows (mostly purchases), not revenue from those parties. AZPIL is Marketing Authorisation Holder (MAH) and import-licence holder in India for the molecules it markets.

  2. Regulatory gateway. AZPIL files for import and marketing permission with India's Central Drugs Standard Control Organisation (CDSCO) for each new molecule or indication from the global pipeline. FY2026 saw 11 approvals; the group cites 25+ new medicines/indications launched in India over three years (press release, 16 Oct 2026).

  3. Commercialisation. Specialty field force calling on oncologists, cardiologists, nephrologists, pulmonologists and hospital formularies, increasingly supplemented by brand-partnership (co-marketing) agreements with large domestic companies (Sun Pharma, Mankind Pharma) for mass-market molecules where AZPIL lacks reach.

  4. Services revenue. Clinical-trial services provided to an overseas group company (the group runs about 80 global clinical trials in India per October 2026 release).

  5. Manufacturing. Historically a tablet manufacturing/packaging site at Yelahanka, Bengaluru. Exit announced Nov 2023; manufacturing licence surrendered Sept 2025; exit completed during FY2026.

Revenue model mix

Revenue typeDescriptionFY2026 disclosure
Product sales (patented/branded Rx)Oncology, Biopharmaceuticals, Rare Disease brands~INR 21,559 M across three therapy areas (computed from disclosed TA revenue)
ServicesClinical-trial services to group companyNot separately disclosed in materials reviewed
Licensing / distribution feesUpfront/consideration from co-marketing partners (e.g., INR 260 M payable under the Nov 2025 Sun Pharma SZC agreement)—
Subscription——

Customers and end-markets

Direct customers: pharmaceutical distributors/stockists (C&F agents), hospitals and institutional buyers (including government tenders for some brands), and co-marketing partners (Sun Pharma, Mankind Pharma) to whom AZPIL supplies product.

Prescribers: medical/surgical oncologists, haemato-oncologists, cardiologists, nephrologists, endocrinologists/diabetologists, pulmonologists, rare-disease specialists.

End-market: the Indian Pharmaceutical Market (IPM), specifically the premium innovator/specialty segment, which is a small share of the generics-dominated IPM by volume but growing faster in value. Patient affordability is a constraint; most oncology therapy is out-of-pocket or insurance-funded, with patient-access programmes playing a material role.

Value-chain position

AZPIL sits at the last mile of AstraZeneca's global value chain: discovery, development and manufacturing occur largely outside the listed entity; AZPIL captures a distribution/commercialisation margin governed by transfer pricing with the parent.

Strategy

Stated strategy (themes from company communications)

  • Pioneer in science, lead in specialist disease areas, transform patient outcomes — the recurring articulation of ambition in filings since 2023.

Accelerate the global pipeline into India: 11 approvals in FY2026; 25+ new medicines/indications in three years.

Focus on three therapy areas: Oncology, Biopharmaceuticals (CVRM, R&I, V&I) and Rare Disease.

New access pathways: working with governments and industry, leveraging AI and solutions across prevention, awareness, diagnosis and treatment (Oct 2026 release); earlier screening and guideline-directed therapy in CVRM.

Asset-light operating model: exit from manufacturing to rely on the global supply network.

Partnership-led reach: brand partnerships with Sun Pharma and Mankind for mass-market molecules.

Geographic penetration: expansion into Tier II/III markets, field-force expansion and digital physician engagement (aggregator description of growth strategy).

Strategic initiatives (last 24 months)

InitiativeDateDescriptionStatus
Manufacturing exit, BengaluruNov 2023 – FY2026Exit site; seek buyer; surrender licenceExit completed FY2026; buyer not confirmed
RestructuringLate 2024>125 roles reportedly eliminatedCompleted
Leadership transitionJul 2025Oncology head promoted to MDIn place
Lokelma launch + Sun Pharma partnershipNov 2025Hyperkalaemia franchise with second-brand partnerLive
Oncology label expansionsOct 2025 – 2026Enhertu (HER2+), Calquence (CLL/SLL; MCL)Approved
Fasenra label expansionsMay & Jul 2026EGPA; HES 12+Approved
Rare Disease build-outFY2025 – FY2027Revenue scaled from ~INR 31 M (implied FY2025) to INR 144 M in a single quarterScaling
Corporate Affairs strengtheningJul 2026Hire of ex-FICCI policy leaderIn place
Mumbai commercial officeOct 202625,600 sq ft office; stakeholder engagement and talentOpened
Investor engagementAug 2026Virtual analyst/investor interaction on 19 Aug 2026Held

Medium-term targets / guidance

AZPIL does not publish numerical revenue or margin guidance. Management commentary is qualitative (sustained innovation-led growth). Parent AstraZeneca PLC's global ambitions (e.g., multi-year revenue targets) are not India-specific and are not reproduced here.

Products & Services

Oncology

Brand (molecule)Description / mechanismKey indicationsTarget prescriberLatest India milestone
Tagrisso (osimertinib)Third-generation EGFR tyrosine-kinase inhibitor, oralEGFR-mutated non-small cell lung cancer (NSCLC), adjuvant and metastaticMedical oncologistsFlagship growth brand [global portfolio]; latest India label expansions not itemised in materials reviewed
Imfinzi (durvalumab)Anti-PD-L1 immunotherapy, IVNSCLC, small-cell lung cancer, biliary tract, hepatocellular carcinoma, othersOncologistsAdditional CDSCO approvals referenced during FY2026 [filed, per aggregator summary]
Imjudo (tremelimumab)Anti-CTLA-4, used with ImfinziHepatocellular carcinoma, NSCLCOncologists—
Lynparza (olaparib)PARP inhibitor, oral (co-commercialised globally with MSD)BRCA-mutated ovarian, breast, prostate, pancreatic cancersGynae-oncologists, oncologists[global portfolio]
Calquence (acalabrutinib) 100 mg tabletsSecond-generation BTK inhibitorUntreated CLL/SLL in combination with venetoclax ± obinutuzumab (CDSCO, Apr 2026); untreated mantle cell lymphoma in transplant-ineligible patients (CDSCO, 2026)Haemato-oncologists[filed] two 2026 approvals
Enhertu (trastuzumab deruxtecan) 100 mg/5 mLHER2-directed antibody-drug conjugate (with Daiichi Sankyo)HER2-positive and HER2-low breast cancer; additional HER2-positive indication approved 3 Oct 2025Oncologists[filed] Oct 2025
Zoladex (goserelin)LHRH agonist implantProstate and breast cancerOncologists, urologistsMature brand [global portfolio]
Faslodex (fulvestrant)Selective oestrogen-receptor degrader, injectionHR+ advanced breast cancerOncologistsMature; generic competition [global portfolio]
Truqap (capivasertib)AKT inhibitorHR+/HER2- advanced breast cancer with pathway alterationsOncologists—
Datroway (datopotamab deruxtecan)TROP2-directed ADCBreast cancer, NSCLCOncologists—

Biopharmaceuticals — Cardiovascular, Renal & Metabolism (CVRM)

Brand (molecule)DescriptionIndicationsNotes
Forxiga (dapagliflozin)SGLT2 inhibitor, oralType 2 diabetes, heart failure, chronic kidney diseaseHistoric largest Biopharma brand; dapagliflozin faces Indian generic competition; Sun Pharma owns Oxra/Oxramet/Oxraduo brands since 2021
Xigduo (dapagliflozin + metformin)Fixed-dose combinationType 2 diabetes[global portfolio]
Brilinta (ticagrelor)P2Y12 antiplateletAcute coronary syndromeReached 9.7% segment share by FY2015 per annual report
Betaloc / Betaloc ZOK (metoprolol)Beta-blockerHypertension, angina, heart failurePrice-controlled; subject of NPPA overcharge demand (Betaloc-50), stayed by Delhi High Court (Aug 2026)
Lokelma (sodium zirconium cyclosilicate) 5 g powder for oral suspensionPotassium binderHyperkalaemia (CKD, heart failure on RAAS inhibitors)Launched Nov 2025; co-marketed by Sun Pharma as Gimliand under Nov 2025 agreement
Crestor (rosuvastatin)StatinDyslipidaemiaMature/genericised [global portfolio]

Biopharmaceuticals — Respiratory & Immunology (R&I) and V&I

Brand (molecule)DescriptionIndicationsNotes
Symbicort Turbuhaler (budesonide + formoterol)ICS/LABA dry-powder inhalerAsthma, COPDExclusive distribution by Mankind Pharma since Mar 2024; NPPA show-cause (Sep 2025) alleging INR 605 M overcharge
Fasenra (benralizumab) 30 mg/mL pre-filled syringeAnti-IL-5 receptor biologicSevere eosinophilic asthma; relapsing/refractory EGPA (CDSCO, 26 May 2026); hypereosinophilic syndrome in patients 12+ (CDSCO, 15–16 Jul 2026)[filed] two 2026 label expansions
Breztri (budesonide/glycopyrronium/formoterol)Triple-therapy inhalerCOPD—
Pulmicort (budesonide)Inhaled corticosteroidAsthmaMature [global portfolio]
Vaccines & Immune TherapiesV&I listed as part of Biopharmaceuticals in Q1 FY2027 disclosureSpecific V&I brands in India not itemised—

Rare Disease (Alexion, AstraZeneca Rare Disease)

Brand (molecule)DescriptionIndicationsNotes
Soliris (eculizumab)C5 complement inhibitorPNH, aHUS, gMG, NMOSDIndia commercial status in listed entity not itemised
Ultomiris (ravulizumab)Long-acting C5 inhibitorPNH, aHUS, gMG—
Koselugo (selumetinib)MEK inhibitorNeurofibromatosis type 1 plexiform neurofibromas—

Rare Disease revenue: INR 215 M in FY2026; INR 144 M in Q1 FY2027.

Services

ServiceDescriptionCounterparty
Clinical-trial servicesSite management, monitoring, safety and regulatory support for global trialsOverseas AstraZeneca group company; group runs ~80 global trials in India

Financial Narrative

Primary source map: FY2026 and FY2025 headline numbers from company results releases (30 May 2025; 26 May 2026). Line items (cost of revenue, operating income) from StockAnalysis (standardised from filings). EBITDA and total income from Anand Rathi data pages. Book value/EPS from Bajaj Broking/Screener. Where aggregator standardisation differs from the company's reported presentation, this is noted.

Income statement: notes and sources

Notes: Total income FY2022–FY2026 per StockAnalysis "revenue as reported" and Anand Rathi (INR 820.36 / 1,029.07 / 1,330.33 / 1,756.92 / 2,304.07 crore). FY2024 PBT of INR 2,195.4 M and PAT INR 1,615.1 M from company filing; FY2022–FY2023 PBT from Screener (rounded crore). Diluted EPS equals basic (no dilutive instruments identified). FY2025 PAT includes the Bengaluru site-closure provision (exceptional); FY2026 PAT is "after exceptional items". EBITDA aggregator definition likely includes other income; treat as indicative.

Margins (computed on revenue from operations, %)

Revenue CAGR FY2022–FY2026: (22,756 / 8,056)^(1/4) − 1 = 29.6%. Ten-year revenue CAGR ~15% (INR 564 crore → INR 2,276 crore, per Craytheon).

Quarterly trajectory

Q3 FY2026 PAT: Anand Rathi shows INR 325.9 M; a CMOTS/Arihant note shows INR 315.5 M (−42.3% YoY) on net sales of INR 6,155.7 M — discrepancy noted; the four FY2026 quarters using INR 325.9 M sum exactly to the FY2026 PAT of INR 1,875.2 M, so that figure is preferred.

Balance sheet

Equity computed as book value per share × 25.0 M shares; FY2024 cross-checks to filing (share capital INR 50.0 M + other equity INR 7,069.2 M = INR 7,119.2 M).

Cash flow and capital returns

Capex should be structurally minimal after the manufacturing exit (office fit-outs, IT). Dividends declared = DPS × 25 M shares; payout = declared ÷ PAT. No buybacks identified.

Ratios

Interest coverage computed from StockAnalysis (interest expense INR 9.5 / 6.3 / 12.0 / 14.6 / 44.9 M — almost entirely lease interest). Screener reports ROCE 33.4% and ROE 23.6% (trailing basis); Craytheon reports FY2026 ROE 21.5%, consistent with the computation above.

Commentary on trends, inflections and drivers

Growth inflection (FY2023 onward): After a flat FY2022 (−1.0%), revenue accelerated to 24–33% annual growth for four consecutive years, led by oncology launches and label expansions (Tagrisso, Imfinzi, Lynparza, Enhertu, Calquence) and by a stepped-up approval cadence (11 in FY2026).

Gross-margin compression is structural, not cyclical: Standardised gross margin fell ~21 points from FY2023 to FY2026 as the mix shifted to imported high-cost oncology biologics/ADCs (where transfer prices leave a thinner distribution margin), the in-house manufacturing contribution disappeared, and price-controlled Biopharma brands were genericised. Operating leverage on fixed costs (SG&A grew only from INR 2,303 M to INR 2,653 M over four years) partially offset this, keeping operating margin in a 10–15% band.

FY2025 dip was exceptional: PAT fell 28% in FY2025 primarily due to site-closure provisions (Q1 FY2025 net loss of INR 117.9 M); FY2026 PAT rebounded 62% to INR 1,875 M.

Renewed margin pressure in 2026: Q4 FY2026 PAT fell 23% despite 20% revenue growth (total expenses +27%), and Q1 FY2027 PAT fell 32% despite 30% revenue growth, with EBITDA margin compressing ~820 bps to ~7.1%. Third-party analysis attributes this to inventory drawdown, elevated employee costs tied to management churn, and foreign-exchange headwinds on imports (CompoundingAI). This divergence is the single most important near-term financial issue.

Shareholder returns: Dividend per share has risen every year (INR 10 → 36), with payout normalising around 40–50% of PAT outside the FY2025 exceptional year.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Units

Business unitWhat it containsRepresentative brands

Oncology

Targeted small molecules, immuno-oncology, antibody-drug conjugates (ADCs), hormonal therapies

Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Zoladex

Biopharmaceuticals

CVRM (Cardiovascular, Renal & Metabolism), R&I (Respiratory & Immunology), V&I (Vaccines & Immune Therapies)

Forxiga, Brilinta, Betaloc, Lokelma, Symbicort, Fasenra, Breztri

Rare Disease

Alexion-derived complement inhibitors and other rare-disease therapies

—

Other operating revenue (computed residual)

Revenue from operations not attributed to the three TAs — likely services, other operating income and minor brands

—

Revenue by Segment

Segment (INR Mn)FY2025FY2026

Oncology revenue (INR Mn)

11,18116,101

Biopharmaceuticals revenue (INR Mn)

4,8915,243

Rare Disease revenue (INR Mn)

31215

Other operating revenue, residual (INR Mn)

1,0601,197

Total revenue from operations (INR Mn)

17,16322,756

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment share of revenue (%)

Segment share of revenue (%)FY2025FY2026

Oncology share (%)

65.170.8

Biopharmaceuticals share (%)

28.523.0

Rare Disease share (%)

0.20.9

Other share (%)

6.25.3

Segment YoY growth (%)

FY2026

—

Oncology growth (%)

44.0—

Biopharmaceuticals growth (%)

7.2—

Rare Disease growth (%)

600—

Total growth (%)

32.6—

Revenue by Segment (Quarterly)

Segment (INR Mn)Q1FY2026Q1FY2027

Oncology revenue (INR Mn)

3,6904,649

Biopharmaceuticals revenue (INR Mn)

1,1901,619

Rare Disease revenue (INR Mn)

4144

Other operating revenue, residual (INR Mn)

379416

Total revenue from operations (INR Mn)

5,2636,828

Income Statement and Per-Share Data

Metric (INR Mn)FY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Mn)

8,05610,03012,95517,16322,756

Total income incl. other income (INR Mn)

8,20410,29113,30317,56923,041

Cost of revenue, standardised (INR Mn)

3,1693,6606,0089,68813,846

Gross profit, standardised (INR Mn)

4,8876,3706,9477,4758,910

Operating income, standardised (INR Mn)

6941,4891,7142,1482,337

EBITDA, aggregator (INR Mn)

1,0091,5102,3571,9782,853

Profit before tax (INR Mn)

8301,3402,1951,5642,522

Net income / PAT (INR Mn)

6169931,6151,1571,875

Basic & diluted EPS (INR)

24.6439.7264.6046.3075.01

Dividend per share (INR)

1016243236

Margin (%)

Margin (%)FY2022FY2023FY2024FY2025FY2026

Gross margin (%)

60.763.553.643.639.2

Operating margin (%)

8.614.813.212.510.3

EBITDA margin (%)

12.515.118.211.512.5

Pre-tax margin (%)

10.313.416.99.111.1

Net margin (%)

7.69.912.56.78.2

Revenue growth YoY (%)

-1.024.529.232.532.6

Net income growth YoY (%)

-34.061.262.7-28.362.0

Income Statement and Per-Share Data (Quarterly)

Metric (INR Mn)Q1FY2026Q2FY2026Q3FY2026Q4FY2026Q1FY2027

Revenue from operations (INR Mn)

5,2635,5906,1205,7866,828

Total income (INR Mn)

5,3765,6536,1675,8466,920

EBITDA, aggregator (INR Mn)

920761514658579

Profit before exceptional items & tax (INR Mn)

75100592510

PAT (INR Mn)

558542326449379

EPS (INR)

22.3321.6913.0417.9515.17

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Shareholders' equity (INR Mn)

5,1145,8877,1197,7048,728

Book value per share (INR)

204.56235.48284.77308.14349.12

Equity share capital (INR Mn)

5050505050

Balance-sheet Item Details

Balance-sheet itemStatus

Total debt

No borrowings identified; "almost debt free" (Screener). Long-term D/E of 0.12 reported by an aggregator most likely reflects Ind AS 116 lease liabilities (office leases)

Goodwill & intangibles

None material identified (no acquisitions)

Cash Flow and Returns & Leverage Ratios (%)

Metric (INR Mn)FY2022FY2023FY2024FY2025FY2026

Net change in cash, aggregator (INR Mn)

960520503100

Dividend declared for the year (INR Mn)

250400600800900

Dividend payout ratio (%)

40.640.337.269.148.0

Share buybacks (INR Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE on year-end equity (%)

12.016.922.715.021.5

Debt / equity

~0 (lease only)

~0

~0

~0

~0.12 incl. leases (aggregator)

Net debt / EBITDA

Net cash

Net cash

Net cash

Net cash

Net cash

Interest coverage (Operating income ÷ interest expense, x)

7323614314752

Revenue by Region and Region Margins & Growth (%)

Geography (INR Mn)FY2025FY2026

India — therapy-area product revenue (INR Mn)

16,10321,559

Residual: other operating revenue incl. overseas group services (INR Mn)

1,0601,197

Total revenue from operations (INR Mn)

17,16322,756

Geography growth (%)

FY2026

—

India therapy-area product revenue growth (%)

33.9—

Residual other operating revenue growth (%)

12.9—

Share Price History

DatePrice (INR)Source

17 Nov 2025

9,135.00

Bajaj Broking

3 Apr 2026

7,827.50

5paisa

10 Apr 2026

8,291.50

Arihant

22 Jul 2026

8,088.50

Kotak Neo

21 Aug 2026

7,415.50

Bajaj Broking / Craytheon

28 Aug 2026

7,121.10

Anand Rathi

23 Sep 2026

6,712.15

Anand Rathi (last dated quote verified)

Undated (likely Oct 2026)

5,950.50

Fyers (shows −34.8% over one year) — not date-verified

Price performance

Value

Basis

1-year return

−23.8%

Anand Rathi, as of 23 Sep 2026

6-month return

−19.0%

Anand Rathi, as of 23 Sep 2026

3-year price CAGR

~8%

—

5-year price CAGR

~14%

Fyers

10-year price CAGR

~20%

Fyers

52-week range

INR 6,606.30 – 9,850.00

Anand Rathi, Sep 2026

All-time/earlier 52-week high

INR 10,691

Screener / 5paisa

Valuation Snapshot

MultipleValueComputation

Market capitalisation (INR Mn)

167,804

6,712.15 × 25.0 M shares

Trailing EPS (INR)

67.85

Q2 FY2026 21.69 + Q3 13.04 + Q4 17.95 + Q1 FY2027 15.17

P/E (TTM)

~98.9x

Matches Anand Rathi 98.93

P/B

~19.2x

On FY2026 BVPS INR 349.12

EV/Sales (TTM, cash not deducted)

~6.9x

On TTM revenue INR 24,324 M

EV/EBITDA (TTM, cash not deducted)

~66.8x

On TTM aggregator EBITDA INR 2,512 M

Dividend yield (FY2026 DPS)

~0.54%

36 ÷ 6,712

Dividend (INR per share)

Dividend (INR per share)FY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

1016243236

Capital Markets

ItemStatus

Credit ratings (Moody's/S&P/Fitch; domestic CRISIL/ICRA/CARE)

None for the listed entity — no rated debt

Debt maturity profile

Not applicable (no borrowings; lease liabilities only)

Analyst consensus

Limited sell-side coverage; no verifiable consensus target or rating identified. Algorithmic "price target" websites are excluded as unreliable

Free float

25% (6.25 M shares); low liquidity (daily volumes of a few thousand to ~50,000 shares in Aug 2026)

Analyst Conclusions

Management guidance

No quantitative guidance. Management messaging (Q1 FY2027 release and Oct 2026 press release) emphasises disciplined execution across Oncology, Biopharmaceuticals and Rare Disease, an innovation-led strategy, new access pathways and the Mumbai commercial hub.

Consensus expectations

No verifiable consensus. Based on run-rate, Q1 FY2027 revenue of INR 6,828 M annualises to ~INR 27,300 M (+20% on FY2026) even with zero sequential growth — this is a mechanical observation, not a forecast.

Bull case

  1. Pipeline flow-through sustains 20%+ growth. FY2026 delivered 11 approvals; 2026 has already added Calquence (two indications) and Fasenra (two indications), and oncology grew 26% in Q1 FY2027 on a high base.

  2. Margin troughing. Q1 FY2027 margin pressure was attributed to transitory factors (inventory drawdown, churn-related employee costs, FX). With manufacturing-exit costs behind it and SG&A historically growing far slower than revenue, operating leverage could restore EBITDA margins toward the 12–15% band seen in FY2023–FY2026.

  3. Optionality from Rare Disease and new categories. Rare Disease jumped to INR 144 M in one quarter; Lokelma/Gimliand creates a two-channel hyperkalaemia franchise.

Bear case

  1. Structural margin erosion. Gross margin has fallen ~21 points in three years as imported biologics dominate the mix; growth may continue to accrue mainly to the parent via transfer pricing.

  2. Regulatory pricing hits. The Symbicort (INR 605 M alleged) and Betaloc-50 matters together could exceed a quarter's PAT if adverse.

  3. Valuation without earnings growth. At ~99x trailing earnings with PAT down YoY in three of the last four quarters (Q3, Q4 FY2026; Q1 FY2027), further de-rating is plausible if margins don't recover.

Catalysts and monitorables (next 12 months)

  • Q2 FY2027 results (expected Nov 2026; date to be confirmed): EBITDA margin vs Q1's ~7.1%.

  • Appointment of a permanent CFO and replacement Medical Affairs director.

  • Outcome of the NPPA Symbicort show-cause; Delhi High Court hearing on Betaloc-50 (10 Feb 2027).

  • CDSCO approvals for further ADC/oncology assets.

  • Rare Disease quarterly run-rate and Lokelma uptake via Sun.

  • Disposition (sale) of the Bengaluru site and any one-off gain or loss.

  • FY2027 dividend recommendation (May 2027).

  • Any parent-level action on the 75% holding (no current indication).

Analyst verdict

AstraZeneca Pharma India is a high-quality growth franchise trapped inside a structurally thin-margin operating model. On the top line, few listed Indian pharma companies can match it: revenue has compounded at roughly 30% a year for four years, oncology is growing 26–44%, and the global parent is pushing an unusually dense stream of molecules and indications through CDSCO. The balance sheet is debt-free, the manufacturing exit is complete, and dividends have risen every year.

The problem is conversion. Because AZPIL imports finished product from its parent at transfer prices it does not control, incremental revenue — especially in high-cost ADCs and biologics — carries progressively less gross margin. That dynamic, plus FX, price-control enforcement and a costly wave of leadership turnover, produced three of the last four quarters with year-on-year PAT declines despite 20–39% revenue growth. Q1 FY2027's ~7% EBITDA margin is the lowest in the recent series.

The valuation does not leave room for that problem to persist. Even after a ~24% one-year decline, the stock trades near 99x trailing earnings and ~19x book, a premium justified only if margins return to the 12–15% range while growth stays above 20%. Minority shareholders also hold a structurally weak hand: the parent owns 75%, sets transfer prices and decides which assets sit in the listed entity.

Our synthesis: the fundamental trajectory is positive and the franchise is strategically important to AstraZeneca's Asia ambitions, but the next two quarters — specifically margin recovery, a stable CFO appointment, and resolution of NPPA matters — determine whether the premium is earned. Until margin evidence improves, the risk-reward is balanced at best, with the burden of proof on profitability rather than growth.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenurePrior roles / backgroundNotes

Praveen Rao Akkinepally

Country President & Managing Director

From 1 Jul 2025 (three-year term)

20+ years at AZ; joined as a microbiologist; Head of Oncology Business Unit, India; Head of Marketing for oncology brands (US); Global Head, Lung Cancer Commercialisation; FICCI Cancer Round Table contributor

—

Bhavana Agrawal

Executive Director & CFO

Until close of business 31 Aug 2026

Moving to a regional AZ Group role; resignation tendered 20 Jul 2026; holds no shares

Board approved a change in her designation on 10 Aug 2026

Tanya Sanish

Company Secretary & Compliance Officer

From 23 Feb 2026

Replaced Manasa R.

—

Praveen K. Mittal

Director, Corporate Affairs

From 6 Jul 2026

30 years in healthcare/medtech policy; 18+ years at FICCI as Assistant Secretary General

Replaced Ajay Sharma (resigned 26 Nov 2025)

Shikha Mirchandani Chatrath

Director – Commercial Excellence, BD & Strategy

Appointed FY2025

—

Per FY2025 release

Amita Bhave

Head, Regulatory Affairs

Appointed FY2025

——

Harish Dash

Senior Director, Commercial IT & Digital

From 3 Mar 2025

——

Amarpreet Kaur Ahuja

Country HR Director

—

Recognised in industry HR listing (FY2025)

—

Executive Leadership Team

NameRoleExit dateContext

Dr Sanjeev Kumar Panchal

MD & Country President

30 Jun 2025

Moved to global AZ role (US)

Pankaj Jain

Head – Legal

31 Oct 2025

Resigned

Ajay Sharma

Director – Corporate Affairs

26 Nov 2025

Resigned

Aditi Mehta

Senior leader (reported variously as Oncology Director / HR)

12 Jun 2026

Resigned; role description inconsistent across secondary sources

Srikanth B.S.

Senior leader (reported as site/operations or supply-chain lead)

15 Jun 2026

Resigned

Bhavana Agrawal

ED & CFO

31 Aug 2026

Regional AZ role

Dr Sandeep Arora

Director – Medical Affairs, Biopharma & Rare Disease BUs

15 Sep 2026

Resigned to pursue external opportunity; replacement search under way

Board of Directors — Shilpa Divekar Nirula

NameCategoryNotes

Shilpa Divekar Nirula

Chairperson, Independent Director

ID since 29 Dec 2021; Chair since 30 Sep 2024; re-appointed for second five-year term from 29 Dec 2026 (AGM Aug 2026)

Revathy Ashok

Independent Director

Co-opted Dec 2016; second-term completion timing should be monitored under the 10-year ID cap

Monica Widhani

Independent Director

Appointed FY2025

Praveen Rao Akkinepally

Managing Director

From 1 Jul 2025; DIN 11137771

Bhavana Agrawal

Executive Director (designation changed Aug 2026; CFO role ended 31 Aug 2026)

—

Arun Krishna

Non-Executive (Additional) Director; AZ Area Vice President, Asia

Appointed Aug 2026

Hooi Bien Chuah

Non-Executive, non-independent Director (AZ nominee)

Reappointed by rotation, AGM 2025

Jesus Javier Diaz Ropero Esteso

Non-Executive Director (AZ nominee)

Appointed FY2025

Major Shareholders

Holder category% of equity

AstraZeneca Pharmaceuticals AB, Sweden (foreign promoter)

75.00

Institutions (total)

8.76

— of which mutual funds (latest pattern quoted)

~6.01

— of which foreign portfolio investors (May 2026)

~2.70

Non-institutions (retail, HNI, corporates)

16.23

Number of shareholders

~29,338

Ownership trend (%)

Jun2025

Promoter holding (%)

75.00

Institutional holding (%)

7.58

Non-institutional holding (%)

17.41

Competitive Landscape

Competitors by Segment

SegmentDirect competitors in IndiaNature of competition

Oncology — lung (EGFR, IO)

Roche (unlisted India affiliate), MSD (Keytruda), Bristol-Myers Squibb, Novartis, Pfizer Ltd; domestic generics/biosimilars (Dr. Reddy's, Natco, Zydus, Intas, Biocon, Hetero)

Innovator class competition + Indian generics of off-patent agents

Oncology — breast/HER2 & ADCs

Roche (trastuzumab/T-DM1), Novartis (CDK4/6), Pfizer, Eli Lilly; biosimilar trastuzumab makers (Biocon, Intas, Zydus)

Enhertu competes against biosimilar-anchored HER2 market

Oncology — haematology (BTK)

Johnson & Johnson (ibrutinib), BeiGene (zanubrutinib), AbbVie; Indian ibrutinib generics

Calquence positioned on tolerability

CVRM — SGLT2/diabetes

Boehringer Ingelheim/Lupin (empagliflozin), Sun Pharma, Mankind, Glenmark, Torrent, Alkem, Cipla, Dr. Reddy's (generic dapagliflozin/empagliflozin)

Intense generic price competition

CVRM — antiplatelet/beta-blockers

Sun Pharma, Torrent, Cipla, Lupin, Intas

Price-controlled, branded generics

CVRM — hyperkalaemia

—

Early-market category creation

R&I — inhalers

Cipla (market leader in inhalation), Glenmark, Lupin, GSK Pharmaceuticals

Cipla dominance; Mankind channel for Symbicort

R&I — biologics (severe asthma)

GSK (mepolizumab), Sanofi (dupilumab), Novartis (omalizumab)

Specialist biologic competition

Rare disease (complement)

Biosimilar eculizumab entrants (e.g., Intas), Novartis (iptacopan)

Price and access

Competitor Detail

BenchmarkAZPIL (FY2026)

Revenue (INR Mn)

22,756

Revenue growth (%)

32.6

Net margin (%)

8.2

R&D intensity

Negligible at listed level

Company Snapshot

$262.8M

Revenue

760

Employees

1979

Founded

Bengaluru, India

Headquarters

SWOT Analysis

Strengths

  • Best-in-class growth: revenue CAGR of 29.6% FY2022–FY2026; fifth consecutive quarter of double-digit growth in Q1 FY2027 (+30%).
  • Oncology franchise scale: INR 16,101 M in FY2026, +44% YoY; INR 4,649 M in Q1 FY2027, +26%.
  • Regulatory cadence: 11 CDSCO approvals in FY2026; 2026 approvals for Calquence (two indications) and Fasenra (two indications).
  • Financial strength: no financial debt; interest expense limited to leases (INR 44.9 M in FY2026); treasury income INR 232 M in FY2026.
  • Shareholder returns: DPS raised every year from INR 10 (FY2022) to INR 36 (FY2026).
  • Partner leverage: Sun Pharma paid INR 260 M under the SZC distribution agreement; Mankind's ~16,000-strong field force distributes Symbicort.

Weaknesses

  • Margin compression: Q1 FY2027 EBITDA margin ~7.1%, down ~820 bps YoY; Q4 FY2026 PAT −23% on revenue +20%.
  • Falling gross margin: standardised gross margin 63.5% (FY2023) → 39.2% (FY2026).
  • Revenue concentration: oncology ~71% of FY2026 revenue.
  • Related-party dependence: related-party transactions with AZ UK/Sweden reported at ~72.9% of FY2025 revenue; transfer pricing set by the parent.
  • Biopharma stagnation: only +7.2% in FY2026.
  • Management depth: at least seven senior-management/KMP exits between Jun 2025 and Sep 2026.

Opportunities

  • ADC and IO expansion: Enhertu label growth (Oct 2025) and potential Datroway/Truqap launches (India status to be confirmed).
  • Rare Disease scale-up: revenue went from ~INR 4 M (implied Q1 FY2026) to INR 144 M (Q1 FY2027).
  • Hyperkalaemia category creation with two brands (Lokelma, Gimliand) across AZ and Sun channels.
  • Severe respiratory biologics: Fasenra in EGPA and HES broadens use beyond asthma.
  • Western-India commercial hub: Mumbai office (Oct 2026) for payer, hospital and government engagement.
  • Clinical-trial hub: ~80 global trials in India support faster local evidence and earlier access.

Threats

  • Pricing enforcement: NPPA Symbicort show-cause (INR 605 M) and Betaloc-50 demand (stayed to Feb 2027).
  • Generic erosion of CVRM molecules (dapagliflozin) and biosimilar competition in oncology/rare disease.
  • FX: INR weakness against European currencies raises import costs (cited as Q1 FY2027 headwind).
  • Valuation de-rating: stock down ~24% over one year to Sep 2026 while still near ~99x trailing P/E.
  • Parent strategic decisions (supply, pricing, portfolio allocation between listed and unlisted AZ India entities) outside minority shareholders' control.
  • Tax disputes: recurring assessment additions (e.g., AY2020-21 INR 131.1 M addition, later deleted).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
30 May 2025FY2025 results: revenue INR 17,162.9 M (+32%); core EPS INR 46.30; INR 32 dividend recommendedGrowth momentum confirmed through closure costs
9–13 Jun 2025Praveen Rao Akkinepally named MD effective 1 Jul 2025; Dr Panchal to global roleOncology leader takes helm
14 Aug 2025Q1 FY2026: revenue +36% YoY; PAT INR 558.3 M; four new therapy approvals. 46th AGM approves INR 32 dividend, MD appointment, secretarial auditorStrong start to FY2026
2 Sep 2025Manufacturing licence surrendered (valid to Dec 2027)Irreversible step in manufacturing exit
11–12 Sep 2025NPPA show-cause notice alleging INR 604.98 M overcharging on Symbicort Turbuhaler; 30-day responsePricing-regulation liability
19 Sep 2025Head–Legal Pankaj Jain resigns (effective 31 Oct 2025)Management turnover begins
3 Oct 2025CDSCO permits import/marketing of Enhertu for an additional HER2-positive indicationOncology label growth
15 Oct 2025Announces Lokelma 5 g launch in India for Nov 2025New CVRM franchise
7 Nov 2025Q2 FY2026 results: revenue +37% YoYPeak growth quarter
17 Nov 2025Second brand partnership with Sun Pharma for SZC; INR 260 M considerationReach extension, partner economics
26 Nov 2025CIT(A) order for AY2020-21 deletes INR 131.1 M addition (favourable impact ~INR 33 M); Director–Corporate Affairs Ajay Sharma resignsTax win; further churn
11 Feb 2026Q3 FY2026: revenue +39% YoY (net sales ~INR 6,156 M), PAT down ~42% YoY to ~INR 316–326 MFirst sign of revenue-profit divergence
23 Feb 2026Tanya Sanish appointed Company SecretaryGovernance continuity
20 Mar 2026Board change
13 Apr 2026CDSCO approval for Calquence (acalabrutinib) with venetoclax ± obinutuzumab in untreated CLL/SLLHaematology-oncology expansion
2026 (Q1 FY2027 window)CDSCO approval for Calquence in untreated mantle cell lymphoma (transplant-ineligible)Further BTK label expansion
26 May 2026FY2026 results: revenue INR 22,755.8 M (+33%), PAT INR 1,875.2 M (+62%); INR 36 dividend; Q4 PAT −23% YoY; 11 approvals in year; Fasenra EGPA approvalRecord year, weak exit quarter
12–15 Jun 2026Two senior leaders (Aditi Mehta, Srikanth B.S.) departExecution-depth concerns
16 Jun 2026Praveen K. Mittal (ex-FICCI) hired as Director, Corporate Affairs, from 6 Jul 2026Policy capability rebuilt
15–16 Jul 2026CDSCO approval of Fasenra for hypereosinophilic syndrome (age 12+)R&I/rare overlap expansion
18 Jul 2026Annual Report 2025-26 and BRSR filed (limited assurance)Disclosure
20–21 Jul 2026CFO Bhavana Agrawal resigns effective 31 Aug 2026 for regional AZ role; record date 31 Jul for INR 36 dividendKMP transition
27 Jul 2026NPPA demand notice alleging overcharging on Betaloc-50 tabletsPricing liability
10 Aug 2026Q1 FY2027: revenue INR 6,828 M (+30%); PAT INR 379 M (−32%); EBITDA margin ~7.1%. 47th AGM: dividend approved; new statutory auditor (FRN 101248W/W-100022); Chair re-appointed; Arun Krishna added to boardTop-line strength, profit weakness
19 Aug 2026Virtual analyst/investor interactionInvestor communication
25 Aug 2026Delhi High Court stays NPPA Betaloc-50 demand until hearing on 10 Feb 2027Liability deferred
15 Sep 2026Director – Medical Affairs (Biopharma & Rare Disease) Dr Sandeep Arora exitsContinued senior churn
Sep 2026Share price falls to ~INR 6,700 (−24% over one year)De-rating
16 Oct 2026Mumbai corporate office inaugurated by Maharashtra CM; group cites nearly 5,000 India colleagues and ~80 global trialsCommercial footprint expansion
Upcoming (Nov 2026, date not yet confirmed)Q2 FY2027 resultsKey test of margin recovery

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Revenue by Segment (FY2025–FY2026): Total revenue from operations rose from INR 17,163 Mn in FY2025 to INR 22,756 Mn in FY2026.
AstraZeneca Pharma India Limited — Revenue by Segment (FY2025–FY2026)
Series (INR Mn)FY2025FY2026
Total revenue from operations17,16322,756
Oncology revenue11,18116,101
Biopharmaceuticals revenue4,8915,243
Rare Disease revenue31215
Other operating revenue, residual1,0601,197

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. NSE filing — Mumbai corporate office press release, 16 Oct 2026 (nsearchives.nseindia.com)
  2. NSE filing — BRSR FY2025-26, 18 Jul 2026 (nsearchives.nseindia.com)
  3. NSE filing — Proceedings of 47th AGM, 10 Aug 2026 (nsearchives.nseindia.com)
  4. NSE filing — Proceedings of 46th AGM, 14 Aug 2025 (nsearchives.nseindia.com)
  5. NSE filing — FY2025 results release, 30 May 2025 (nsearchives.nseindia.com)
  6. NSE filing — Q2 FY2026 board outcome, 7 Nov 2025 (nsearchives.nseindia.com)
  7. NSE filing — Sun Pharma SZC agreement, 17 Nov 2025 (nsearchives.nseindia.com)
  8. NSE filing — Mankind Symbicort agreement, 11 Mar 2024 (nsearchives.nseindia.com)
  9. NSE filing — Board meeting intimation FY2026 results (nsearchives.nseindia.com)
  10. BSE filing — Q1 FY2025 results notice (bseindia.com)
  11. BSE filing — Statutory auditor reappointment (2021) (bseindia.com)
  12. BSE filing — Sun Pharma Oxra trademark acquisition (2021) (bseindia.com)
  13. DSIJ — Q1 FY2027 results (insights.dsij.in)
  14. CompoundingAI — Q1 FY2027 analysis (compoundingai.in)
  15. FilingReader — FY2026 annual summary (filingreader.com)
  16. Kotak Neo / NDTV Profit — Q4 FY2026 results (kotakneo.com)
  17. StockAnalysis — income statement (stockanalysis.com)
  18. Anand Rathi — share price and financials (anandrathi.com)
  19. Screener — company page (screener.in)
  20. IIFL — shareholding pattern (indiainfoline.com)
  21. Chola Securities — shareholding and NPPA Betaloc update (cholasecurities.com)
  22. Fierce Pharma — manufacturing licence surrender (fiercepharma.com)
  23. Outlook Business / PTI — Bengaluru plant exit (2023) (outlookbusiness.com)
  24. Medical Dialogues — MD appointment (medicaldialogues.in)
  25. Board Stewardship — MD profile (boardstewardship.com)
  26. ScanX — AGM 2026 notice and CFO resignation (scanx.trade)
  27. AskFuzz — CFO resignation (askfuzz.ai)
  28. Investywise — Medical Affairs director resignation (investywise.com)
  29. Arihant Capital — Calquence CLL approval (arihantcapital.com)
  30. Muthoot Securities — Fasenra HES approval (muthootsecurities.com)
  31. Biospectrum — Sun Pharma SZC partnership (biospectrumindia.com)
  32. Chemistry World — Bengaluru R&D closure (2014) (chemistryworld.com)
  33. Medical Dialogues Business — 2016 chairman change (business.medicaldialogues.in)
  34. Pharmafile — Sun Pharma dapagliflozin deal (2016) (pharmafile.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.